- cafead Feb 09, 2022 at 11:02: AM
via Pharmaceutical products developed in China could have a steep hill to climb to be approved for use within the United States, impacting the plans of several large companies who hoped to capitalize on clinical data accumulated in that country.
This morning, The Wall Street Journal reported that the U.S. Food and Drug Administration is slowing down the process of potentially approving dozens of new medications that had initially been developed for the Chinese market. Regulators are expressing concern over the clinical studies that were used to approve the use of those medications in China.
article source
This morning, The Wall Street Journal reported that the U.S. Food and Drug Administration is slowing down the process of potentially approving dozens of new medications that had initially been developed for the Chinese market. Regulators are expressing concern over the clinical studies that were used to approve the use of those medications in China.
article source